BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) is a blank-check company focused on the oncology and biopharmaceutical sector, targeting businesses engaged in cancer therapeutics development and related life sciences verticals. The company filed an 8-K with the Securities and Exchange Commission on May 12, 2026, under accession number 0001193125-26-219801, disclosing a material corporate event. HLXB operates within the healthcare-focused SPAC segment, which has drawn sustained attention from institutional investors seeking exposure to late-stage oncology pipelines through structured acquisition vehicles. Sponsor information and full deal timeline details are tracked across the SpacDesk database. Sign up at SpacDesk for complete filing history, status updates, and deal analytics on HLXB and hundreds of active SPACs.